Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study checks how well RA drug works in real life

NCT ID NCT01394276

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how well the drug tocilizumab (Actemra) works for people with moderate to severe rheumatoid arthritis in everyday medical practice. Researchers followed 322 adults for 12 months after starting treatment. The main goals were to see how many patients achieved low disease activity or remission after 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tocilizumab (RoActemra/Actemra)
What this could lead to
If successful, this study could confirm that tocilizumab works well in everyday clinical practice for controlling rheumatoid arthritis symptoms.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only follows patients for 12 months, so long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

322 people

The number who actually took part.

Start date

May 2011

Finished

Apr 2013

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria * Initiated on RoActemra/Actemra treatment according to the Summary of Product Characteristics not more than 6 months before opening of study center Exclusion Criteria: * Current serious infection * Hypersensitivity to the active component or any of the excipients * Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • Study site

    Coppito, Abruzzo, 67100, Italy

  • Study site

    Pescara, Abruzzo, 65100, Italy

  • Study site

    Brindisi, Apulia, 72100, Italy

  • Study site

    Casarano (LE), Apulia, 73042, Italy

  • Study site

    Foggia, Apulia, 71100, Italy

  • Study site

    Martina Franca, Apulia, 74015, Italy

  • Study site

    San Cesario di Lecce, Apulia, 73016, Italy

  • Study site

    Reggio Calabria, Calabria, 89133, Italy

  • Study site

    Avellino, Campania, 83100, Italy

  • Study site

    Gragnano, Campania, 80054, Italy

  • Study site

    Naples, Campania, 80131, Italy

  • Study site

    Naples, Campania, 80138, Italy

  • Study site

    Naples, Campania, 80144, Italy

  • Study site

    Salerno, Campania, 84131, Italy

  • Study site

    Telese Terme, Campania, 82037, Italy

  • Study site

    Bologna, Emilia-Romagna, 40138, Italy

  • Study site

    Ferrara, Emilia-Romagna, 44100, Italy

  • Study site

    Modena, Emilia-Romagna, 41100, Italy

  • Study site

    Piacenza, Emilia-Romagna, 29100, Italy

  • Study site

    Trieste, Friuli Venezia Giulia, 34142, Italy

  • Study site

    Albano Laziale, Lazio, 00041, Italy

  • Study site

    Rome, Lazio, 00128, Italy

  • Study site

    Rome, Lazio, 00145, Italy

  • Study site

    Rome, Lazio, 00152, Italy

  • Study site

    Rome, Lazio, 00168, Italy

  • Study site

    Rome, Lazio, 00189, Italy

  • Study site

    Viterbo, Lazio, 01100, Italy

  • Study site

    Arenzano, Liguria, 16011, Italy

  • Study site

    Castel Goffredo, Lombardy, 46042, Italy

  • Study site

    Gavardo, Lombardy, 25085, Italy

  • Study site

    Legnano, Lombardy, 20025, Italy

  • Study site

    Milan, Lombardy, 20157, Italy

  • Study site

    Monza, Lombardy, 20052, Italy

  • Study site

    Pavia, Lombardy, 27100, Italy

  • Study site

    Rozzano, Lombardy, 20089, Italy

  • Study site

    Saronno, Lombardy, 21047, Italy

  • Study site

    Treviglio, Lombardy, 24047, Italy

  • Study site

    Vimercate, Lombardy, 20059, Italy

  • Study site

    Agnone, Molise, 86081, Italy

  • Study site

    Cuneo, Piedmont, 12100, Italy

  • Study site

    Novara, Piedmont, 28100, Italy

  • Study site

    Turin, Piedmont, 10126, Italy

  • Study site

    Sassari, Sardinia, 07100, Italy

  • Study site

    Catania, Sicily, 95124, Italy

  • Study site

    Gazzi, Sicily, 98125, Italy

  • Study site

    Palermo, Sicily, 90127, Italy

  • Study site

    Palermo, Sicily, 90146, Italy

  • Study site

    Ancona, The Marches, 60020, Italy

  • Study site

    Iesi, The Marches, 60035, Italy

  • Study site

    Florence, Tuscany, 50139, Italy

  • Study site

    Massa, Tuscany, 54100, Italy

  • Study site

    Pisa, Tuscany, 56100, Italy

  • Study site

    Prato, Tuscany, 59100, Italy

  • Study site

    Perugia, Umbria, 06122, Italy

  • Study site

    Verona, Veneto, 37126, Italy

  • Study site

    Verona, Veneto, 37134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.